Certoparin
drugOn this page
Summary
Certoparin (CHEMBL4297724) is a phase-3 clinical-stage oligosaccharide; indicated across 3 conditions including atrial fibrillation and kidney failure.
At a glance
- Status: Max clinical phase 3 (not approved)
- Modality: Oligosaccharide
- Indications: 3 conditions
- Clinical trials: 5
Identifiers
Drug identity and classification
| Field | Value |
|---|---|
| ChEMBL ID | CHEMBL4297724 |
| Name | Certoparin |
| Type | Oligosaccharide |
| Max phase | 3 |
Also known as: Certoparin, CERTOPARIN
Targets
Targets
No target linkage available.
Bioactivity
No ChEMBL bioactivity rows at pChembl ≥ 5 (expected for biologics / antibodies).
Target pathways
No target-pathway data for this drug (no mapped target genes).
Indications & clinical
Indications
3 indications (0 at ChEMBL trial phase 4). Phase below is the highest clinical-trial phase recorded for this drug against each disease — not the molecule’s overall approval status (that is in the Summary).
| Indication | Trial phase | MONDO | EFO |
|---|---|---|---|
| atrial fibrillation | 3 | MONDO:0004981 | EFO:0000275 |
| kidney failure | 1 | MONDO:0001106 | HP:0000083 |
1 further indication record had no mapped disease name (EFO/MeSH-only) or were duplicates, and are omitted.
Clinical trials
Total trials: 5.
Phase distribution
| Phase | Trials |
|---|---|
| PHASE3 | 4 |
| PHASE1/PHASE2 | 1 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT00171769 | PHASE3 | COMPLETED | Atrial Fibrillation Feasibility Certoparin Trial - AFFECT |
| NCT00311753 | PHASE3 | COMPLETED | Efficacy and Safety of Low-molecular Weight Heparin for Thromboprophylaxis in Acutely Ill Medical Patients |
| NCT00451412 | PHASE3 | COMPLETED | A Comparison of Certoparin and Unfractionated Heparin in the Prevention of Thromboembolic Events in Acutely Ill Medical Patients |
| NCT01179620 | PHASE3 | COMPLETED | Certoparin in Renal Patients Undergoing Hemodialysis |
| NCT01660295 | PHASE1/PHASE2 | COMPLETED | Pharmacokinetics of Certoparin in Subjects With Renal Insufficiency and Healthy Subjects |
Clinical evidence (CIViC)
No CIViC predictive evidence (expected for non-precision-medicine drugs).
Pharmacology
Pharmacogenomics
No PharmGKB pharmacogenomic data curated for this drug.
Related molecules
Related molecules
No competitor molecules sharing a primary target (ChEMBL phase ≥2 or PubChem drug-class).
Related Atlas pages
- Diseases: atrial fibrillation